ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02565758. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Study identification
- NCT ID
- NCT02565758
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 85 participants
Conditions and interventions
Conditions
Interventions
- ABBV-085 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 17, 2015
- Primary completion
- Mar 24, 2019
- Completion
- Mar 24, 2019
- Last update posted
- Apr 4, 2019
2015 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona /ID# 148582 | Phoenix | Arizona | 85054 | — |
| Scottsdale Healthcare /ID# 151349 | Scottsdale | Arizona | 85258-4566 | — |
| University of California, Los Angeles /ID# 148586 | Los Angeles | California | 90095 | — |
| Univ of Colorado Cancer Center /ID# 148581 | Aurora | Colorado | 80045 | — |
| University of Chicago /ID# 148579 | Chicago | Illinois | 60637-1443 | — |
| Dana-Farber Cancer Institute /ID# 143782 | Boston | Massachusetts | 02215 | — |
| Washington University-School of Medicine /ID# 151348 | St Louis | Missouri | 63110 | — |
| NYU Langone Medical Center /ID# 150786 | New York | New York | 10016-6402 | — |
| Duke Univ Med Ctr /ID# 148200 | Durham | North Carolina | 27710 | — |
| Carolina BioOncology Institute /ID# 148583 | Huntersville | North Carolina | 28078 | — |
| University of Pennsylvania /ID# 148576 | Philadelphia | Pennsylvania | 19104-5502 | — |
| Greenville Hospital System /ID# 148652 | Greenville | South Carolina | 29605 | — |
| Mary Crowley Cancer Research /ID# 148580 | Dallas | Texas | 75230 | — |
| Univ TX, MD Anderson /ID# 147681 | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics /ID# 141715 | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialists /ID# 148584 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02565758, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2019 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02565758 live on ClinicalTrials.gov.